Skip to content

AtriCure ATRC Accrued liabilities

Accrued liabilities at other companies

Avanos Medical logo
Avanos MedicalAVNS
-$33.7M-128%
Pulse Biosciences, Inc. logo
Pulse Biosciences, Inc.PLSE

Other financials

Income statement

See full
Revenue$141.2M+14.3%
Gross profit$109.3M+18.0%
Operating income$526.0K+109%
Net income$108.0K+102%
EPS (diluted)$0.00+100%

Balance sheet

See full
Cash & equivalents$146.2M+46.3%
Total debt$76.2M-3.1%
Total equity$491.7M+8.2%
Total assets$644.0M+8.8%

Cash flow

See full
Operating cash flow-$4.0M+63.8%
CapEx$3.9M+76.6%
Free cash flow-$7.8M+40.6%

Valuation

See full
Market cap$1.43B-9.9%
Enterprise value$1.36B-13.1%
P/S2.6×-0.7×

Profitability

See full
Gross margin75.6%+0.8pp
Operating margin-5.1%-1.3pp
Net margin-5.6%-1.5pp
FCF margin9.7%

Returns & leverage

See full
Return on equity-6.1%-1.3pp
Debt / equity0.2×0.0×
Current ratio4.3×+0.2×

Where this comes from

Reported directly by AtriCure in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.

The official record: AtriCure’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about AtriCure's accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AtriCure's accrued liabilities?
AtriCure (ATRC) reported accrued liabilities of -$13.51M in Q1 2026.
How has AtriCure's accrued liabilities changed year-over-year?
AtriCure's accrued liabilities decreased by 7.5% year-over-year, from -$12.56M to -$13.51M.
What is the long-term trend for AtriCure's accrued liabilities?
Over 2 years (2021 to 2025), AtriCure's accrued liabilities has grown at a -10.9% compound annual growth rate (CAGR), from $8.81M to $7M.